Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Woodard

Clinical Cardiac Electrophysiology Pensacola, FL Medical Doctor

NPI 1598736670 CMS profile 163335

8333 N Davis Hwy Fl 4, Ste 1-1100, Pensacola, FL 32514

Open in the dashboard

General payments

$16,056

181 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$151,075 paid to institutions, not to them · program years 2019–2023

Through program year 2025, David Woodard of Pensacola, FL is reported in the CMS Open Payments database as having received $16,056 across 181 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $151,075 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 46th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,542 26
2024 General $700 28
2023 General $1,563 40
2022 General $885 31
2021 General $8,422 31
2020 General $536 15
2019 General $1,409 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Woodard
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to David Woodard were reported at $2,542. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year David Woodard Clinical Cardiac Electrophysiology median Middle half National median
2019 $1,409 $2,361 $585–$8,260 $163
2020 $536 $993 $247–$4,351 $114
2021 $8,422 $1,185 $326–$4,739 $132
2022 $885 $2,073 $554–$6,789 $149
2023 $1,563 $2,568 $759–$8,159 $160
2024 $700 $2,557 $703–$7,403 $164
2025 $2,542 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Aziyo Biologics, Inc. $8,696 16 payments
  2. Abbott Laboratories $4,012 63 payments
  3. Stryker Corporation $892 10 payments
  4. Medtronic, Inc. $671 9 payments
  5. E.R. Squibb & Sons, L.L.C. $476 23 payments
  6. Pfizer Inc. $179 10 payments
  7. Impulse Dynamics (USA) Inc. $179 3 payments
  8. Edwards Lifesciences Corporation $147 2 payments
  9. Baxter Healthcare $101 4 payments
  10. Novartis Pharmaceuticals Corporation $87 6 payments
  11. Other $617 35 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Honoraria $6,458 3 payments
  2. Food and Beverage $6,226 162 payments
  3. Travel and Lodging $3,023 15 payments
  4. Grant $349 1 payment
Products named General payments · program years 2019–2025
  1. ECM Patch,Pouch $8,696 16 payments
  2. AVEIR $1,512 12 payments
  3. Micra $612 7 payments
  4. SALVATION $339 8 payments
  5. INSPACE $338 1 payment
  6. Quadra Allure MP RF CRT Pacemkr $316 4 payments
  7. ELIQUIS $300 13 payments
  8. Allure Quadra RF CRT Pacemaker $272 3 payments
  9. Assurity Pacemaker $270 6 payments
  10. Fortify Assura, Ellipse ICD $220 3 payments
  11. Other $3,416 122 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 40 drugs

Part D claims

2,612

Median for Internal Medicine: 777

Drug cost

$602,202

Median for Internal Medicine: $73,373

Branded share of claims

30.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 320 $353,679
Entresto Sacubitril/Valsartan Brand 92 $97,325
Xarelto Rivaroxaban Brand 66 $71,549
Multaq Dronedarone Hcl Brand 34 $40,258
Repatha Sureclick Evolocumab Brand 14 $11,029
Metoprolol Succinate Generic 275 $3,422
Ranolazine Er Ranolazine Brand 36 $3,168
Flecainide Acetate Generic 36 $2,536
Atorvastatin Calcium Generic 176 $2,142
Nebivolol Hcl Generic 19 $2,045

The 10 drugs with the highest cost, of 40 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 65 billing codes

Paid by Medicare

$175,408

Medicare's payments for the services billed

Medicare patients

1,117

Average age 77

Services billed

3,325

568 women, 549 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 59%
Ischemic heart disease 52%
Atrial fibrillation 44%
Diabetes 42%
Chronic kidney disease 40%
Heart failure 38%
COPD 31%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $131
  • PFIZER INC. $21
$152 320 —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $109
$109 — —
Arcalyst
  • Kiniksa Pharmaceuticals International, plc $53
$53 — —
VERQUVO
  • Merck Sharp & Dohme Corporation $24
$24 — —
NEXLETOL
  • Esperion Therapeutics, Inc. $20
$20 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

181 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record